These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 19252432)

  • 21. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy.
    Lanning RM; Morrow M; Riaz N; McArthur HL; Dang C; Moo TA; El-Tamer M; Krause K; Siu C; Hsu M; Zhang Z; Pei X; McCormick B; Powell SN; Ho A
    Ann Surg Oncol; 2015 Aug; 22(8):2517-25. PubMed ID: 25564167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
    J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers.
    Horio A; Fujita T; Hayashi H; Hattori M; Kondou N; Yamada M; Adachi E; Ushio A; Gondou N; Sueta A; Yatabe Y; Iwata H
    Int J Clin Oncol; 2012 Apr; 17(2):131-6. PubMed ID: 21681642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
    Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
    Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Locoregional recurrence in patients with HER2 positive breast cancer.
    Brollo J; Kneubil MC; Botteri E; Rotmensz N; Duso BA; Fumagalli L; Locatelli MA; Criscitiello C; Lohsiriwat V; Goldhirsch A; Leonardi MC; Orecchia R; Curigliano G
    Breast; 2013 Oct; 22(5):856-62. PubMed ID: 23642529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The predictive value of HER2 in breast cancer.
    Piccart M; Lohrisch C; Di Leo A; Larsimont D
    Oncology; 2001; 61 Suppl 2():73-82. PubMed ID: 11694791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
    Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
    Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
    Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study.
    Campiglio M; Bufalino R; Sasso M; Ferri E; Casalini P; Adamo V; Fabi A; Aiello R; Riccardi F; Valle E; Scotti V; Tabaro G; Giuffrida D; Tarenzi E; Bologna A; Mustacchi G; Bianchi F; Balsari A; Ménard S; Tagliabue E
    Breast Cancer Res Treat; 2013 Aug; 141(1):101-10. PubMed ID: 23942848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
    Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
    Perez EA; Dueck AC; McCullough AE; Reinholz MM; Tenner KS; Davidson NE; Gralow J; Harris LN; Kutteh LA; Hillman DW; Jenkins RB; Chen B
    J Natl Cancer Inst; 2012 Jan; 104(2):159-62. PubMed ID: 22138096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues.
    Cao L; Sun PL; Yao M; Jia M; Gao H
    Hum Pathol; 2017 Oct; 68():166-174. PubMed ID: 28899737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.